Zacks: Brokerages Anticipate Aclaris Therapeutics Inc (NASDAQ:ACRS) Will Announce Quarterly Sales of $5.77 Million

Equities analysts predict that Aclaris Therapeutics Inc (NASDAQ:ACRS) will report sales of $5.77 million for the current quarter, according to Zacks. Three analysts have provided estimates for Aclaris Therapeutics’ earnings. The highest sales estimate is $6.48 million and the lowest is $5.20 million. Aclaris Therapeutics reported sales of $3.68 million during the same quarter last year, which would suggest a positive year over year growth rate of 56.8%. The firm is scheduled to issue its next earnings results on Friday, August 2nd.

According to Zacks, analysts expect that Aclaris Therapeutics will report full year sales of $23.16 million for the current year, with estimates ranging from $20.80 million to $25.81 million. For the next financial year, analysts expect that the business will report sales of $36.47 million, with estimates ranging from $19.90 million to $53.94 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that cover Aclaris Therapeutics.

Aclaris Therapeutics (NASDAQ:ACRS) last issued its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.86) by ($0.05). The company had revenue of $5.04 million for the quarter, compared to analyst estimates of $5.13 million. Aclaris Therapeutics had a negative return on equity of 78.05% and a negative net margin of 999.53%.

Several equities research analysts have issued reports on the stock. Zacks Investment Research downgraded shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, May 21st. ValuEngine upgraded shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, April 1st. BidaskClub upgraded shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, May 8th. Finally, Cantor Fitzgerald cut their price objective on shares of Aclaris Therapeutics from $50.00 to $24.00 and set an “overweight” rating for the company in a research report on Wednesday. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $19.69.

Shares of ACRS stock opened at $4.65 on Thursday. The company has a debt-to-equity ratio of 0.16, a current ratio of 4.33 and a quick ratio of 4.30. The company has a market cap of $200.16 million, a price-to-earnings ratio of -1.15 and a beta of 1.48. Aclaris Therapeutics has a 12-month low of $4.27 and a 12-month high of $21.97.

In other news, major shareholder James E. Flynn sold 614,710 shares of Aclaris Therapeutics stock in a transaction that occurred on Friday, May 10th. The shares were sold at an average price of $6.13, for a total value of $3,768,172.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 14.80% of the stock is currently owned by insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Citigroup Inc. raised its position in shares of Aclaris Therapeutics by 3,200.0% in the fourth quarter. Citigroup Inc. now owns 3,993 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 3,872 shares in the last quarter. Great West Life Assurance Co. Can acquired a new stake in shares of Aclaris Therapeutics in the fourth quarter valued at approximately $43,000. BNP Paribas Arbitrage SA raised its position in shares of Aclaris Therapeutics by 82,200.0% in the first quarter. BNP Paribas Arbitrage SA now owns 7,407 shares of the biotechnology company’s stock valued at $44,000 after buying an additional 7,398 shares in the last quarter. Legal & General Group Plc raised its position in shares of Aclaris Therapeutics by 64.1% in the fourth quarter. Legal & General Group Plc now owns 6,495 shares of the biotechnology company’s stock valued at $48,000 after buying an additional 2,536 shares in the last quarter. Finally, Virtu Financial LLC acquired a new stake in shares of Aclaris Therapeutics in the first quarter valued at approximately $70,000. Institutional investors own 91.79% of the company’s stock.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies for dermatological and immuno-inflammatory diseases in the United States. It operates in two segments, Dermatology Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor; and RHOFADE, an oxymetazoline hydrochloride cream.

Read More: What defines an oversold asset?

Get a free copy of the Zacks research report on Aclaris Therapeutics (ACRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Zacks: Brokerages Anticipate Aclaris Therapeutics Inc (NASDAQ:ACRS) Will Announce Quarterly Sales of $5.77 Million

Equities analysts predict that Aclaris Therapeutics Inc (NASDAQ:ACRS) will report sales of $5.77 million for the current quarter, according to Zacks. Three analysts have provided estimates for Aclaris Therapeutics’ earnings. The highest sales estimate is $6.48 million and the lowest is $5.20 million. Aclaris Therapeutics reported sales of $3.68 million during the same quarter last year, which would suggest a positive year over year growth rate of 56.8%. The firm is scheduled to issue its next earnings results on Friday, August 2nd.

According to Zacks, analysts expect that Aclaris Therapeutics will report full year sales of $23.16 million for the current year, with estimates ranging from $20.80 million to $25.81 million. For the next financial year, analysts expect that the business will report sales of $36.47 million, with estimates ranging from $19.90 million to $53.94 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that cover Aclaris Therapeutics.

Aclaris Therapeutics (NASDAQ:ACRS) last issued its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.86) by ($0.05). The company had revenue of $5.04 million for the quarter, compared to analyst estimates of $5.13 million. Aclaris Therapeutics had a negative return on equity of 78.05% and a negative net margin of 999.53%.

Several equities research analysts have issued reports on the stock. Zacks Investment Research downgraded shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, May 21st. ValuEngine upgraded shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, April 1st. BidaskClub upgraded shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, May 8th. Finally, Cantor Fitzgerald cut their price objective on shares of Aclaris Therapeutics from $50.00 to $24.00 and set an “overweight” rating for the company in a research report on Wednesday. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $19.69.

Shares of ACRS stock opened at $4.65 on Thursday. The company has a debt-to-equity ratio of 0.16, a current ratio of 4.33 and a quick ratio of 4.30. The company has a market cap of $200.16 million, a price-to-earnings ratio of -1.15 and a beta of 1.48. Aclaris Therapeutics has a 12-month low of $4.27 and a 12-month high of $21.97.

In other news, major shareholder James E. Flynn sold 614,710 shares of Aclaris Therapeutics stock in a transaction that occurred on Friday, May 10th. The shares were sold at an average price of $6.13, for a total value of $3,768,172.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 14.80% of the stock is currently owned by insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Citigroup Inc. raised its position in shares of Aclaris Therapeutics by 3,200.0% in the fourth quarter. Citigroup Inc. now owns 3,993 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 3,872 shares in the last quarter. Great West Life Assurance Co. Can acquired a new stake in shares of Aclaris Therapeutics in the fourth quarter valued at approximately $43,000. BNP Paribas Arbitrage SA raised its position in shares of Aclaris Therapeutics by 82,200.0% in the first quarter. BNP Paribas Arbitrage SA now owns 7,407 shares of the biotechnology company’s stock valued at $44,000 after buying an additional 7,398 shares in the last quarter. Legal & General Group Plc raised its position in shares of Aclaris Therapeutics by 64.1% in the fourth quarter. Legal & General Group Plc now owns 6,495 shares of the biotechnology company’s stock valued at $48,000 after buying an additional 2,536 shares in the last quarter. Finally, Virtu Financial LLC acquired a new stake in shares of Aclaris Therapeutics in the first quarter valued at approximately $70,000. Institutional investors own 91.79% of the company’s stock.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies for dermatological and immuno-inflammatory diseases in the United States. It operates in two segments, Dermatology Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor; and RHOFADE, an oxymetazoline hydrochloride cream.

Read More: What defines an oversold asset?

Get a free copy of the Zacks research report on Aclaris Therapeutics (ACRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit